________________________________________________________________________________________________________________________
Center of Excellence for Lenti, the US for AAV, and then France for many of the other vectors we work with. We can do development work for Lenti in all three of our geographies, and will expand this model for other vectors, which means that we’ re able to support clients with fast-track programs.”
As gene and cell therapy treatments continue to boom across the biomedical sector, OXB’ s work on viral vector platforms remains more important than ever. By maintaining its focus on innovation, quality excellence, and client centricity, the company will continue to champion its high standards of safety, reliability, costeffectiveness, and quality, both presently and in the decades to come.
“ Following the recent acquisition of our new site in Durham, North Carolina, a key priority for us is to continue our focus on integration, getting all parts of the site aligned with the OXB ways of
48